Drug intelligence / Profile preview

ADI-212

Development stage

Phase 2

Lead developer

Adicet Bio

Modality

CRISPR-Cas12 → CRISPR Systems → Programmable Nucleases → Gene Editing → Gene Therapies, Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, CRISPR-Cas13 → CRISPR Systems → Programmable Nucleases → Gene Editing → Gene Therapies, Cytosine Base Editors → Base Editing → Gene Editing → Gene Therapies, TALENs → Other Nucleases → Programmable Nucleases → Gene Editing → Gene Therapies, Standard Prime Editors → Prime Editing → Gene Editing → Gene Therapies, Zinc Finger Nucleases → Other Nucleases → Programmable Nucleases → Gene Editing → Gene Therapies, Adenine Base Editors → Base Editing → Gene Editing → Gene Therapies, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, CRISPR-Cas9 → CRISPR Systems → Programmable Nucleases → Gene Editing → Gene Therapies, Enhanced Prime Editors → Prime Editing → Gene Editing → Gene Therapies

Administration

Intravenous